Antheia uses synthetic biology to produce biosynthetic KSMs and APIs for essential medicines through engineered microbial fermentation.
Antheia has raised $24.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.
Antheia's investors include National Science Foundation, Silicon Valley Bank, Civilization Ventures, America’s Frontier Fund, Viking Global Investors.
Antheia is headquartered in Menlo Park, United States.
Antheia uses synthetic biology to produce biosynthetic KSMs and APIs for essential medicines through engineered microbial fermentation.
Antheia is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Antheia — Funding & Investors." VCBacked, January 27, 2026, https://www.vcbacked.co/company/antheia. Accessed September 16, 2026.
VCBacked. (2026). Antheia — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/antheia
{{cite web |title=Antheia — Funding & Investors |url=https://www.vcbacked.co/company/antheia |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated